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Background: Mycoplasmas-contamination of Orientia tsutsugamushi, one of the obligated intracellular bacteria, is a very
serious problem in in vitro studies using cell cultures because mycoplasmas have significant influence on the results of
scientific studies. Only a recommended decontamination method is to passage the contaminated O. tsutsugamushi
strains through mice to eliminate only mycoplasmas under influence of their immunity. However, this method
sometimes does not work especially for low virulent strains of O. tsutsugamushi which are difficult to propagate in mice.
In this study, we tried to eliminate mycoplasmas contaminants from both high virulent and low virulent strains of the
contaminated O. tsutsugamushi by repeating passage through cell cultures with antibiotics in vitro.
Results: We cultured a contaminated, high virulent strain of O. tsutsugamushi using a mouse lung fibroblasts cell line,
L-929 cell in the culture medium containing lincomycin at various concentrations and repeated passages about every
seven days. At the passage 5 only with 10 μg/ml of lincomycin, we did not detect mycoplasmas by two PCR based
methods whereas O. tsutsugamushi continued good growth. During following four passages without lincomycin,
mycoplasmas did not recover. These results suggested that mycoplasmas were completely eliminated from the high
virulent strain of O. tsutsugamushi. Furthermore, by the same procedures with 10 μg/ml of lincomycin, we also
eliminated mycoplasmas from a contaminated, low virulent strain of O. tsutsugamushi. Our additional assay showed that
50 μg/ml of lyncomycin did not inhibit the growth of O. tsutsugamushi, although MICs of many mycoplasmas
contaminants were less than 6 μg/ml as shown previously.
Conclusion: Our results showed an alternative method to eliminate mycoplasmas from the contaminated O.
tsutsugamushi strains in place of in vivo passage through mice. Especially this notable method works for the
decontamination not only from the high virulent strain also from the low virulent strain of O. tsutsugamushi. For further
elimination, lincomycin at the limit concentration, which does not inhibit the growth of O. tsutsugamushi, can possibly
eliminate most mycoplasmas from contaminated O. tsutsugamushi strains.
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The contamination of cell cultures by mycoplasmas is a
serious problem because these bacteria have multiple
effects on cell cultures and also have a significant influ-
ence on the results of scientific studies. The mycoplas-
mas are not harmless bystanders and thus cannot be
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reproduction in any medium, provided the orVarious elimination methods were previously reported
[1-3]. These methods are mainly based on four general
procedures, physical, chemical, immunological and che-
motherapeutic treatment. The physical procedures in-
clude heat treatment and filtration. The chemical
procedures, treatments to detergents and other chemi-
cals which are effective only against mycoplasmas, but
not against host cells. The immunological procedures in-
clude in vitro co-culture with macrophages and specific
anti-mycoplasmas antisera and in vivo passage thorough
mice. The chemotherapeutic procedures are mainly anti-
biotics treatments that are kills mycoplasmas.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of scrub typhus is one of the obligated intracellular bac-
teria [4]. The mycoplasmas-contaminations of O. tsutsu-
gamushi is also very serious in the in vitro studies using
cell cultures. Furthermore the most effective methods
for elimination of mycoplasmas can not be applied for
decontamination of O. tsutsugamushi strains because
these methods also inhibit the growth of O. tsutsuga-
mushi. Decontamination methods should have strong ef-
fect on mycoplasmas, but have minimum or no effect on
O. tsutsugamushi. Only the recommended decontamin-
ation method is to passage the contaminated O. tsutsuga-
mushi strains through mice. Mouse immunity possibly
eliminates only mycoplasmas, although O. tsutsugamushi
can survive in its target cells, mainly endothelial cells,
splenocytes and hepatocytes. In fact, homogenized spleen
of infected mice is generally used for the next inoculation.
However, this method sometimes does not work especially
for low virulent strains of O. tsutsugamushi because they
are generally difficult to propagate in mice.
Some of the antibiotics, which are used for elimination
of mycoplasmas from tissue culture, are supposed to
have less effect against O. tsutsugamushi according to
the differences of minimum inhibitory concentrations
(MICs) of antibiotics between mycoplasmas [5-7] and O.
tsutsugamushi [8]. In this study, we tried to eliminate
mycoplasmas from contaminated O. tsutsugamushi
strains by repeating passages through cell cultures with
antibiotics in vitro.
Results and discussion
According to the MICs of antibiotics in the previous
reports [5,7-9], we used two antibiotics, lincomycin and
ciprofloxacin for elimination of mycoplasmas from the
contaminated O.tsutsugamushi strains (Table 1). Both
lincomycin and ciprofloxacin are effective against myco-
plasmas. Unfortunately there is no available information
about the MICs of lincomycin against O. tsutsugamushi.
However, according to the MICs of lincomycin against
gram-negative bacteria [10], lincomycin is supposed to
be much less effective against O. tsutsugamushi becauseTable 1 Minimum inhibitory concentrations (MICs) of
antibiotics used in this study
Antibiotics Drug class MICs against Orientiaa) MICs against
mycoplasmasb)
Lincomycin Lincosamide No available data 0.25–2 μg/mL
Ciprofloxacin New Quinolone 6.25–25 μg/mL 0.125–2 μg/ml
Gentamicin Aminoglycoside No available datac) 2.5–500 μg/mL
Kanamicin Aminoglycoside No available data 2.5–500 μg/mL
Minocycline Tetracycline 0.024–0.195 μg/mL 0.016–32 μg/mL
MICs were obtained from previous reports. a) from [8] and b) from [5-7].
c) Gentamycin was not effective against Orinetia tsutsugamushi in a mouse
model [25].O. tsutsugamushi is one of the gram-negative bacteria.
For the example, the MICs of lincomycin against Escher-
ichia coli, one of the typical gram gram-negative bacteria
are more than 50 times higher than those against myco-
plasmas. Ciprofloxacin was also less effective against O.
tsutsugamushi. The MICs of ciprofloxacin against O.
tsutsugamushi are about 3 to 200 times higher than
those against mycoplasmas (Table 1).
Our result of the direct sequencing showed that Ikeda
and Kuroki strains of O. tsutsugamushi were contami-
nated with Mycoplasma hominis and M. orale respect-
ively. M. hominis and M. orale are 10 to 30% of
contaminants of cell cultures (Table 2) [11]. Previous
reports showed that M. fermentas, M. hyorhinis, M. argi-
nini and Acholeplasma laidlawii are the most common
contaminants as well as M. hominis and M. orale. More
than 90% of the contaminants were caused by these six
mycoplasmas [11,12]. The TaqMan PCR and the nested
PCR can detect not only all the 6 most common con-
taminants also some other mycoplasmas. These facts
suggested that the detection methods were very reliable
to monitor mycoplasmas-contaminations in this study.
For elimination of mycoplasmas, we first cultured a con-
taminated, high virulent Ikeda strain of O. tsutsugamushi
using L-929 cell in the culture medium containing linco-
mycin and ciprofloxacin and repeated the passages
(Figure 1). Lincomycin and ciprofloxacin were used at
100, 10 and 1 μg/ml. However, ciprofloxacin at 100 μg/ml
were cytotoxic against L-929 cell in the first assay and
was omitted from the further analyses. We checked
mycoplasma-contaminations and O. tsutsugamushi-growth
at each passage by the two PCR based methods and/or an
immunofluorescent (IF) staining (see Additional file 1).
From the passage 1 to 2 with 10 μg/ml of lincomycin, the
real-time PCR showed that mycoplasmas decreased,
whereas O. tsutsugamushi did not decrease. At the passage
4 with the same concentration of lincomycin, the real-
time PCR did not detect mycoplasmas, however the
nested PCR still detected them. At the passage 5, both the
real-time PCR and the nested PCR did not detect myco-
plasmas, whereas the flourish growth of O. tsutsugamushi
was observed by IF staining. We continued to culture with
lincomycin until the passage 6. During following passages
from 7 to 10 without lincomycin, mycoplasmas did not re-
cover. These results clearly showed that mycoplasmas
were completely eliminated from O. tsutsugamushi-
infected cells. However, the cultivation with 100 μg/ml of
lincomycin as well as 10 and 1 μg/ml of ciprofloxacin
decreased both mycoplasmas and O. tsutsugamushi-
growths, whereas the cultivation with 1 μg/ml of lincomy-
cin did not influence the neither growths.
By the same procedure of Ikeda strain, we cultured a con-
taminated, low virulent Kuroki strain of O. tsutsugamushi
with lincomycin at 10 μg/ml (Figure 1). Mycoplasmas and
Table 2 Major mycoplasmas, and their detection and sequencing methods in this study












Most common contaminant species





Mycoplasma hyorhinis 10%-40% + + Match HUB-1 NC_014448.1
Mycoplasma orale 20%-30% + + Partial Match ATCC 23714D gi|315440428
Mycoplasma arginini 20%-30% No Data + Partial Match G230 gi|290575476
Acholeplasma laidlawii 5%-20% + + Match PG-8A CP000896
Mycoplasma hominis 10%-20% + + Match ATCC 23114 M57675
Other species
Mycoplasma arthritidis No Data + No Data Match 158L3-1 NC_011025.1
Mycoplasma bovis No Data + No Data Match PG45 NC_014760.1
Mycoplasma buccale No Data + No Data No data - -
Mycoplasma faucium No Data + No Data No data - -
Mycoplasma gallisepticum No Data + No Data Match PG31 X16462
Mycoplasma genitalium No Data + + Match ATCC33530 X16463
Mycoplasma hyopneumoniae No Data + No Data Match 7448 NC_007332.1
Mycoplasma penetrans No Data + No Data Match HF-2 NC_004432.1
Mycoplasma pneumoniae No Data + + Match FH X55768
Mycoplasma primatum No Data + No Data No data - -
Mycoplasma salivarium No Data + + Partial Match ATCC 23064D gi|313575713
Ureaplasma parvum No Data + No Data Match ATCC 33697 AF270770
Mycoplasma zalophi No Data No Data No Data Match CSL 4296 gi|148536300
Mycoplasma mycoides No Data No Data No Data Match PG1 gi|126252003
Mycoplasma capricolum No Data No Data No Data Match ATCC 27343 gi|83319253
Mycoplasma agalactiae No Data No Data No Data Match PG2 gi|148291314
Mycoplasma pyrum No Data No Data + No data - -
a) Upper 6 species of mycoplasmas are the most common contaminants of cell cultures [11,12].
b) This broad-range TaqMan PCR can detect many species of mycoplasmas [22].
c) This nested PCR is highly sensitive, and it is used to check for mycoplasma contamination in the Cell Bank of BioResource Centre, Riken Tsukuba Institute,
Tsukuba, Ibaraki, Japan [21].
d) PCR assay for sequencing of mycoplasmas designed in this study. Partial Match means that 2 or 3 of the total of 4 nested-PCR primers match to available
regions of the tuf gene on the public database.
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the IF assay respectively (see Additional file 2). At the pas-
sage 8, the nested PCR did not detect mycoplasmas. We
then continued to cultivate it with lincomycin until the
passage 11. During following passages from 12 to 14 with-
out lincomycin, mycoplasmas did not recover. These
results showed that we successfully eliminated mycoplas-
mas also from the low virulent Kuroki strain. The elimin-
ation length of Kuroki strain was longer than that of Ikeda
strain probably because numbers and/or antibiotics-
susceptibility of the contaminated mycoplasmas were dif-
ferent. For further elimination of mycoplasmas from other
strains of O. tsutsugamushi, we should first evaluate amaximum concentration of lincomycin that does not in-
fluence O. tsutsugamushi-growth, and then apply it for
decontamination because maximum effects against myco-
plasmas are necessary to eliminate them for a short time
and to avoid producing lincomycin-resistant mycoplasmas
[13-15] during repeating passages. Our additional assay
showed that lincomycin at 25 μg/ml did not affect the
growth (the virulent strain), whereas 50 μg/ml slightly
decreased (did not inhibit) the growth in the IF assay
(Table 3). Many previous reports about antibiotics-
susceptibilities of isolated mycoplasmas showed that MICs
of lyncomycin against M. hominis, M. fermentas and A.
laidlawii, which are the major contaminants, were less
Figure 1 Illustrations of decontamination of mycoplasma-contaminated O. tsutsugamushi strains by repeating passage through cell
cultures with antibiotics. Ikeda is a high virulent strain, whereas Kuroki is a low virulent strain, which is difficult to propagate in mice. LCM:
lincomycin, CPFX: ciprofloxacin, Myco: mycoplasmas, Ots: O. tsutsugamushi.
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vious report showed that lincomycin at 50 μg/ml success-
fully eliminated the other major contaminants of
mycoplasmas, M. hyorhinis and M. hominis from cell cul-
tures [19]. However, a previous report showed that some
isolates of M. hyorhinis were highly resistant to lyn-
comycin (MICs > 100 μg/ml) [14] and a few reports
showed that other species of mycoplasmas but not
major species of contaminants were highly resistant
to lyncomycin [13,15]. Considering these facts, linco-
mycin at 50 μg/ml can possibly eliminate the con-
taminants from many of other contaminated strains
of O. tsutsugamushi, although it might not be effect-
ive for all the cases.
Conclusions
Our results showed an alternative method to eliminate
mycoplasmas from the mycoplasma-contaminatedTable 3 The growth of O. tsutsugamushi at the various
concentrations of lincomycin
Concentrations of lincomycin in the culture
medium
12.5 μg/ml 25 μg/ml 50 μg/ml 100 μg/ml
O. tsutsugamsuhi-growtha) +++ +++ ++ -
a) A virulent Ikeda strain was cultivated using L-929 cell in the culture medium
containing lyncomycin at the indicated concentrations. The growth was
observed by the immunofluorescent staining.strains of O. tsutsugamushi in place of in vivo passage
through mice. Especially this new method works for the
decontamination not only from the high virulent strain
also from the low virulent strain of O. tsutsugamushi,
which is difficult to propagate in mice. For further elim-
ination, lincomycin at the limit concentration, which
does not inhibit the growth of O. tsutsugamushi, can
possibly eliminate most mycoplasmas from contami-
nated O. tsutsugamushi strains.
Methods
Cell lines
A mycoplasmas-free L-929 cell (a mouse fibroblast cell
line, JCRB9003) [20] was grown in Eagle’s minimum es-
sential medium (MEM, Wako Co. Ltd., Tokyo, Japan)
supplemented with 5 to 10% of mycoplasma-free, heat-
inactivated FCS (Sigma-Aldrich Japan Co. LCC., Tokyo,
Japan) at 37°C in 5% CO2.
Mycoplasmas-contaminated O. tsutsugamushi strains for
elimination
A mycoplasmas-contaminated high virulent Ikeda strain
and a low virulent Kuroki strain of O. tsutsugamushi
were used for elimination. These strains were acciden-
tally contaminated during a long passage history prob-
ably because mycoplasmas-contaminated cell culture was
used for propagation of these strains. The mycoplasma-
free L-929 cell was used for propagation as mentioned in
the previous section.
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Major mycoplasmas are listed in Table 2. Upper 6 species
are the most common contaminants in cell cultures
[11,12]. In order to monitor mycoplasmas, we extracted
DNA from O. tsutsugamushi-infected L-929 cell with a
commercial DNA extract kit (Tissue genomic DNA extrac-
tion mini kit, Favorgen biotech corporation, Ping-Tung,
Taiwan) and detected mycoplasmas by two high sensitive
and broad range PCR based methods for detection, the
nested PCR [21] and the real-time PCR (TaqMan PCR)
[22]. The nested PCR is used to check mycoplasma-con-
taminations in the Cell Bank of Bioresource Centre, Riken
Tsukuba institute, Tsukuba, Ibaraki, Japan. For determin-
ation of mycoplasma species, we designed new sequencing
primers against tuf gene (Table 2). These designed primers
matched tuf gene of 19 mycoplasmas on the public data-
base. All the primers and the probe are listed in Table 4.
Detection of O. tsutsugamushi
To monitor the growth of O. tsutsugamushi, we used a
real-time PCR against the gene encoding 47kDa com-
mon antigen (Table 4). We extracted DNA from O. tsu-
tsugamushi-infected L-929 cell as mentioned in the
previous section and performed the real-time PCR
according to the general procedure [23]. We also used
an IF staining to monitor the growth of O. tsutsuga-
mushi. In this staining, human convalescent sera of a
scrub typhus patient, which were permitted by the ethics
committee (number 255), and anti-human antibodyTable 4 Primers and probes for detection and sequencing in
Targets Assay
Mycoplasmas
tuf genea) real-time PCR
tuf gene Sequencing 1st
Sequencing 2nd
16s-23s rRNA intergenic spacer region nested PCR 1st
nested PCR 2nd
Orientia tsutsugamushi
47kDa common antigen coding gene real-time PCR
a) Locked nucleic acid (LNA) bases (underlined) and was synthesized with the fluor
and a dark quencher to the 3’ end.
b) TaqMan probe was synthesized with the fluorescent reporter 6-carboxyfluoresceconjugated with AlexaFluorW488 (Life technologies Japan
Ltd, Tokyo, Japan) were used. A part of the infected cells
were harvested and fixed on a glass slide with ice cold
acetone and then the slide was applied for the IF staining
according to the previous reports [24].
Antibiotics
Lincomycin (Wako Pure Chemical Industries, Ltd., Osaka,
Japan) and ciprofloxacin (Wako Pure Chemical Industries,
Ltd., Osaka, Japan) were used for elimination of mycoplas-
mas in this study. Kanamycin and gentamycin are rou-
tinely used for propagation of O. tsutsugamushi to avoid
accidental bacterial contamination in our laboratory be-
cause they do not influence O. tsutsugamushi-growth [25].
Elimination of mycoplasmas from O. tsutsugamushi-
infected cells with antibiotics
We cultured the contaminated strains of O. tsutsuga-
mushi using L-929 cell in the culture medium containing
lincomycin and ciprofloxacin at 100, 10 and 1 μg/ml in
25cm2 tissue culture flask, and repeated passages about
every seven days. At each passage, the infected cells were
harvested. One-third of the harvested cells was used for
the next inoculation, another one-third was used for
DNA extraction, and the remaining one-third was frozen
and stocked. Elimination of mycoplasmas was checked
by the nested PCR and/or real-time PCR. The growth of
O. tsutsugamushi was monitored by the real-time PCR
and/or the IF staining.this study















escent reporter 6-carboxyfluorescein (FAM) covalently coupled to the 5’ end
in (FAM) covalently coupled to the 5’ end and a dark quencher to the 3’ end.
Ogawa et al. BMC Microbiology 2013, 13:32 Page 6 of 6
http://www.biomedcentral.com/1471-2180/13/32Additional files
Additional file 1: Decontamination of a mycoplasma-contaminated,
high-virulent strain of Orientia tsutsugamushi (Ikeda strain) by
repeated passages with antibiotics.
Additional file 2: Decontamination of a mycoplasma-contaminated,
low-virulent strain of Orientia tsutsugamushi (Kuroki strain).
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